{"id":"NCT00000143","sponsor":"Johns Hopkins Bloomberg School of Public Health","briefTitle":"Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT)","officialTitle":"Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"1997-05","primaryCompletion":"2000-06","completion":"2000-06","firstPosted":"1999-09-24","resultsPosted":"2016-03-14","lastUpdate":"2016-03-14"},"enrollment":61,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Cytomegalovirus Retinitis","HIV Infections"],"interventions":[{"type":"DEVICE","name":"Ganciclovir implant and oral ganciclovir","otherNames":["Vitraset"]},{"type":"DRUG","name":"Cidofovir intravenous","otherNames":["Vistide"]}],"arms":[{"label":"Ganciclovir implant and oral ganciclovir","type":"EXPERIMENTAL"},{"label":"Cidofovir IV (Intravenous)","type":"EXPERIMENTAL"}],"summary":"To compare the newest CMV retinitis drug, cidofovir, with a regimen of the ganciclovir intraocular device plus oral ganciclovir with respect to efficacy in preventing vision loss.\n\nTo compare a treatment regimen that incorporates highly active local therapy (ganciclovir device) with a treatment regimen that does not.","primaryOutcome":{"measure":"Survival","timeFrame":"3 years","effectByArm":[{"arm":"Ganciclovir Implant and Oral Ganciclovir","deltaMin":31,"sd":null},{"arm":"Cidofovir IV (Intravenous)","deltaMin":30,"sd":null}],"pValues":[]},"eligibility":{"minAge":"13 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":10,"exclusionCount":4},"locations":{"siteCount":19,"countries":["United States"]},"refs":{"pmids":["11292409","15076943"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":31},"commonTop":[]}}